上皮性卵巢癌患者中血清CA125、HE4、SMRP及细胞因子IL-8、IL-17联合检测意义分析

Significances of join-detection of serum CA125,HE4,SMRP and cytokines IL-8,IL-17 in patients with epithelial ovarian cancer

目的:分析血清CA125、HE4、SMRP及细胞因子IL-8、IL-17在上皮性卵巢癌(EOC)患者中联合检测的意义。方法:选取我院住院卵巢肿瘤患者83例,其中EOC患者41例,其中卵巢良性肿瘤者42例,选择同期体检的健康者42例为对照组,比较EOC组、卵巢肿瘤良性组及对照组的3种肿瘤标记物和2种细胞因子的表达水平,分析5种标记物在EOC临床病理组织类型及临床分期中的水平。结果:EOC组血清CA125、HE4、SMRP和细胞因子IL-8、IL-17水平均显著高于卵巢肿瘤良性组及健康对照组,差异具有统计学意义(P<0.05),卵巢肿瘤良性组与健康对照组各项指标间比较无显著性差异(P>0.05)。EOC患者病理Ⅲ~IV期患者CA125、HE4、SMRP和细胞因子IL-8、IL-17水平均显著高于病理分期为I~Ⅱ期EOC患者,差异具有统计学意义(P<0.05)。病理类型为浆液性EOC患者CA125、HE4、SMRP、IL-8、IL-17显著高于病理类型为粘液性EOC患者,CA125、HE4、IL-8显著高于病理类型为内膜样性EOC患者,差异有统计学意义(P<0.05);病理类型为内膜样性EOC患者CA125、HE4、SMRP、IL-17显著高于病理类型为粘液性EOC患者,差异有统计学意义(P<0.05)。结论:血清CA125、HE4、SMRP及细胞因子IL-8、IL-17在上皮性卵巢癌中高表达,且与病理分期和病理类型有关,有助于疾病的早期诊断和病情判断。

Objective： To analyze the significances of join-detection of serum CA125, HE4, SMRP and cytokines IL-8, 1L-17 in patients with epithelial ovarian cancer. Methods： A total of 83 patients with ovarian tumor from May 2013 to May 2016 in our hospital were selected. Among these, there are 41 patients with EOC and 42 patients with benign ovarian tumor. At the same time, 42 cases of healthy people from health examination department were selected as control group. Expression levels of the 3 tumor markers and the 2 cytokines were compared. The levels of the 5 markers in the clinical pathological types and clinical stages of EOC were analyzed. Results： Serum CA125, HE4, SMRP and cytokines IL-8, IL-17 in EOC group were （258.47 ±54.09） U/L, （237.41±12.48） pmol/L, （7.36±2.17） nmol/L, （76.33±9.73） ng/mL, （23.89±7.12） pg/mL, respectively, which were higher than that in the benign ovary tumor group and healthy control group significantly. And the difference was considered to be statistically significant （P〈0.05）. The comparison of indexes between benign ovary tumor group and healthy control group was not considered to be statistically significant （P〉0.05）. Serum CA125, HE4, SMRP and cytokines IL-8, IL- l7 in EOC patients with Pathological Ill-IV stage were （382.45±40.74） U/L, （276.19±46.13） pmol/L, （9.36±3.11） nmol/ L, （89.06±4.27） ng/mL, （33.52±2.63） pg/mL respectively, which were higher than that in EOC patients with Pathological Ⅰ-Ⅱ stage significantly. And the difference was considered to be statistically significant （P〈0.05）. Serum CA125, HE4, SMRP and cytokines IL-8, IL-17 in EOC patients with serous type was significantly higher than that in EOC patients with mucinous type. CA125, HE4, IL-8 in EOC patients with serous type were significantly higher than that in EOC patients with endometrial type. And the difference was considered to be statistically significant （P〈0.05）. CA125, HE4, SMRP, IL-17 in EOC patients with endometrial type were higher than that in EOC patients with mucinous type. And the difference was considered to be statistically significant （P〈0.05）. Oonclusions： The over expression of serum CA125, HE4, SMRP and cytokines IL-8, IL-17 in patients with epithelial ovarian cancer was related to pathological stage and pathological type, which is helpful to the early diagnosis and condition judgment.